

DOW CHEMICAL CO /DE/  
Form 8-K  
February 11, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**  
**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 11, 2014**

**THE DOW CHEMICAL COMPANY**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**2030 Dow Center, Midland, Michigan**

**1-3433**  
**(Commission**

**File Number)**

**38-1285128**  
**(IRS Employer**

**Identification No.)**

**48674**

**(Address of principal executive offices)**  
**(989) 636-1000**

**(Zip Code)**

**(Registrant's telephone number, including area code)**

**N.A.**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

Dow's Board and executive management team, in conjunction with external advisors, previously and recently conducted an evaluation as part of a broad and thorough review of the Company's strategic options. Attached is the presentation originally used for the Company's 4Q13 Earnings Release on January 29, 2014 (referencing the review on Slide 15) which presentation has been updated with Slide 15-A to further identify and confirm that review and the Company's strategic pathway.

This information is furnished pursuant to Item 7.01 of Form 8-K. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.

The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information in this Item 7.01 is material information that is not otherwise publicly available.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

Exhibit No.	Description
99.1	4Q13 Earnings Release Presentation, Updated on February 11, 2014

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE DOW CHEMICAL COMPANY

Registrant

Dated: February 11, 2014

By: /s/ Charles J. Kalil  
Name: Charles J. Kalil  
Title: Executive Vice President, General  
Counsel and Corporate Secretary

**EXHIBIT INDEX**

<i>Exhibit No.</i>	<i>Description</i>
99.1	4Q13 Earnings Release Presentation, Updated on February 11, 2014